daunorubicin has been researched along with epothilone a in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bukowska, B; Marczak, A; Rogalska, A | 3 |
| Brys, M; Bukowska, B; Forma, E; Marczak, A; Rogalska, A | 1 |
1 review(s) available for daunorubicin and epothilone a
| Article | Year |
|---|---|
New potential chemotherapy for ovarian cancer - Combined therapy with WP 631 and epothilone B.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Epothilones; Female; Humans; Ovarian Neoplasms | 2016 |
3 other study(ies) available for daunorubicin and epothilone a
| Article | Year |
|---|---|
WP 631 and Epo B synergize in SKOV-3 human ovarian cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Daunorubicin; Drug Synergism; Epothilones; Female; Humans; Ovarian Neoplasms | 2014 |
Caspases and ROS - dependent mechanism of action mediated by combination of WP 631 and epothilone B.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Daunorubicin; DNA Damage; DNA Repair; Drug Synergism; Epothilones; Female; Humans; Membrane Potential, Mitochondrial; Ovarian Neoplasms; Reactive Oxygen Species | 2014 |
Why a Combination of WP 631 and Epo B is an Improvement on the Drugs Singly - Involvement in the Cell Cycle and Mitotic Slippage.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Proteins; Daunorubicin; Drug Synergism; Drug Therapy, Combination; Epothilones; Female; Humans; Mitosis; Ovarian Neoplasms; Real-Time Polymerase Chain Reaction; Tumor Cells, Cultured | 2016 |